2025 — HERVs as therapeutic targets across neurodegenerative disorders

One-paragraph summary

Comprehensive review of HERV biology, derepression mechanisms, and therapeutic-targeting strategies across neurodegenerative and neuroinflammatory disorders. Focuses on HERV-W and HERV-K as the most-pathologically-relevant families. Cross-condition framework spans MS, ALS, Alzheimer's, and broader neurodegenerative spectrum. Reviews preclinical studies and clinical trials, particularly monoclonal-antibody approaches (temelimab framing for HERV-W). For the project, this paper reinforces the cross-condition framing the v0.3.3 §14 section just articulated — HERV-targeted therapy as a cross-disease platform rather than indication-specific. Anchor citation for v0.4 architectural reframing toward cross-condition mechanism-research positioning.

Claims as triples

• HERV_reactivation — bridges → multiple_sclerosis [evidence: cross-condition therapeutic-target review; confidence: established]
• HERV_reactivation — bridges → amyotrophic_lateral_sclerosis [evidence: cross-condition review; confidence: emerging]
• HERV_reactivation — bridges → fm_central_only [evidence: cross-condition framework extends to FM via HERV-W ENV; confidence: emerging]
• temelimab — modulates → HERV_W_ENV [evidence: review of mAb-targeting clinical-stage approaches; confidence: established (reinforces existing edge)]

Triangulation notes

• Cross-condition framing anchor. Supports the v0.3.3 §14 claim that HERV-targeted therapy operates as a cross-disease platform.
• Compatible with the herv-targeted-clinical-development-watchlist.md's posture that positive readouts in any HERV-positive indication validate the FM advanced-therapy tier.
• Discovered via watchlist query WL-1.